Foldax is a clinical-stage company that has developed the world’s first synthetic polymer aortic and mitral heart valves. The company is delivering non-thrombogenic heart valves at dramatically lower costs to existing artificial or tissue valves.
Year Founded: 2013
Key Executives:
Ken Charhut, Executive Chairman of the Board
Frank Maguire, COO
Foldax is targeting India for the first approval of its polymer mitral surgical heart valve. The...
Read moreFoldax®, Inc., a leader in the development of innovative, polymer heart valves, today announced positive 30-day...
Read moreFoldax®, Inc., a leader in the development of innovative, polymer heart valves, today announced that its...
Read moreFoldax® Inc., a pioneer in the development of innovative, polymer heart valves, today announced a manufacturing...
Read moreFoldax announced completion of enrollment in the Indian clinical trial of the TRIA™ polymer surgical mitral...
Read moreFoldax announced that the first 30 patients have been treated outside of the U.S., in the...
Read moreFoldax announced that it has executed an agreement with Australia’s national science agency, CSIRO, for full...
Read moreFoldax Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of...
Read moreFoldax announced that the first patients have been enrolled in the Drugs Controller General of India...
Read more